European life sciences investment firm, Medicxi, has launched a $400 million ‘Medicxi IV’ to continue supporting “asset-focused” biotechs that are delivering transformative therapies for patients.
Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full-drug development continuum. It is one of the largest platforms in Europe for scientific entrepreneurs and drug hunters, with a core team of 35 dedicated investment and drug development professionals.
The firm invests in early and late-stage therapeutics with a product vision that can fulfil a clear unmet medical need. Among its current 43 portfolio companies are some from Switzerland, including Swiss biotech startups such as ObsEVa, Molecular Partners and GlycoVaxyn.
With Offices in the UK, Geneva and Jersey, Medicxi attributes its longstanding success to its strong ties to pharmaceutical companies and its extensive team of world-class subject-matter experts, drug hunters and developers, who act as partners for the innovators they are investing in.
With the new fund, Medicxi aims to continue its pioneering ‘asset-centric’ investment model, backing visionary biopharma entrepreneurs and drug hunters along the full drug development spectrum.
Giovanni Mariggi, Partner at Medicxi, added: "With Medicxi IV, we will continue to work with leading scientists and clinicians to create asset-focused companies based on deep domain expertise. Together with our extensive network of drug developers, we will accelerate the development of novel therapies for patients."
(Press release/RAN)
0Comments
Please login or sign up to comment.
Commenting guidelines